We show that MsDef1 targets dual tumor specific targets namely MDR biomarker GlcCer in cancer cells and Trx, liberating ceramide and ASK1 protein from GlcCer and Trx respectively and in the process activating dual cell death pathways. This evidence concerns the gene MAP3K5 and neoplasm.